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ABSTRACT
Background: Idiopathic pulmonary fibrosis (IPF) is a severe and progressive lung disease with a poor
prognosis. Patients with IPF suffer from a high symptom burden, which impairs their health-related quality of
life (HRQoL). Lack of research on IPF symptoms and their clustering, however, makes symptom-centred care
challenging.
Methods: We sent two questionnaires, RAND 36-Item Health Survey and Edmonton Symptom Assessment
System, to 300 patients from the FinnishIPF registry. Of the 300 patients, 245 (82%) responded. We performed
an exploratory factor analysis on the results to search for potential clustering of symptoms into factors.
Results: We found three distinct symptom factors: the emotional factor (including depression, anxiety,
insomnia, loss of appetite and nausea), the pain factor (pain at rest or in movement) and the respiratory
symptoms factor (shortness of breath, cough, tiredness and loss of wellbeing). Correlation was strong within the
factors (ρτ 0.78–0.85) and also evident between them. The factors correlated with the different dimensions of
HRQoL: the emotional factor with mental health (correlation coefficient=−0.69) and vitality (−0.63), the pain
factor with bodily pain (−0.72) and the respiratory symptoms factor with vitality (−0.69), general health (−0.64)
and physical functioning (−0.62).
Conclusion: We found three distinct symptom factors in IPF, of which respiratory and emotional factors
showed the strongest association with decreasing HRQoL. Routine assessment of IPF patients’ respiratory
symptoms, mental health and pain are important as these may be linked with other symptoms and significantly
impair the patient’s HRQoL.
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Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease that impairs the health-related quality of life
(HRQoL) of patients. Prognosis is poor, as only one in four patients survive 5 years after the diagnosis [1–5].
A high symptom burden, together with the varying progression rate of the disease, calls for early integrated
palliative care [1, 6, 7]. However, the targeting and timing of symptom-centred care is difficult, because there
is only a limited number of studies on symptoms and their impact on HRQoL in IPF patients.
The most common symptoms of IPF are shortness of breath and cough [8], which may start months or
even years before the diagnosis [9, 10]. Tiredness, anxiety, depression and pain are also reported by IPF
patients [5]. An Australian study on IPF patients showed that dyspnoea, cough and depression had a high
impact on HRQoL of patients [3], while moderate to severe dyspnoea correlated with a diminished
HRQoL in all domains also in a Finnish study on IPF [5]. Although there are studies on individual
symptoms of IPF patients, information on their concomitant occurrence and overall impact on HRQoL is
needed to guide comprehensive symptom-centred care.
Studying clustering of symptoms may lead to the discovery of interrelated symptoms, and thereby help
clinicians to understand the spectrum and interconnectedness of the symptoms associated with a
particular disease. In factor analysis, a factor is a group or a cluster of known variables associated with a
latent variable. By extension, we defined a symptom factor as a cluster of symptoms connected by an
underlying variable. Clustering of symptoms has been studied in advanced cancer [11, 12], COPD [13],
asthma [14], sleep apnoea [15] and lung cancer [16, 17]. To the best of our knowledge, despite a high
symptom burden in IPF, no studies on symptom clustering in IPF have been published.
To understand the overall symptom burden in IPF, we explored whether identifiable symptom factors exist
in a well-documented real-life cohort of IPF patients, and whether these factors have an impact on HRQoL.
Methods
FinnishIPF registry study
FinnishIPF, initiated in 2012, is a clinical prospective registry study of Finnish IPF patients. Virtually all
IPF patients in Finland are at first evaluated in public central or university hospitals. The FinnishIPF
registry includes all IPF patients, who have given informed consent to take part in the study, from these
specialist centres. The diagnosis of IPF is made in accordance with the European Respiratory Society/
American Thoracic Society 2011/2015/2018 criteria [18–20]. A detailed description of the FinnishIPF
study has been presented by KAUNISTO et al. [21].
Patients
300 IPF patients included in the FinnishIPF registry study were approached by mail in April 2015 and
asked for a written informed consent to participate in our substudy on HRQoL in IPF [5]. Of these 300
patients, 42 refused to participate, 6 turned out not to have IPF, 3 died before answering the first
questionnaire, 2 had received lung transplantation and 2 did not complete the Edmonton Symptom
Assessment System (ESAS) questionnaire; thus, a total of 245 patients formed the final study population.
We used several different questionnaires to assess HRQoL in our study population [5, 22]. For this paper, we
analysed the results of the modified ESAS [23] and the RAND 36-Item Health Survey (RAND-36) [24].
Questionnaires
The ESAS symptom-based questionnaire measures pain, nausea, tiredness, insomnia, shortness of breath,
wellbeing, depression, anxiety and loss of appetite on a numeric rating scale (NRS) from 0 (no symptoms)
to 10 (the worst possible symptoms) [23]. The ESAS questionnaire allows the inclusion of additional
symptoms. Thus, we added cough to the questionnaire and divided pain into pain at rest and pain in
movement. Originally developed for cancer patients, ESAS is also frequently used to assess other patients in
palliative care [23]. In ESAS, a symptom score ⩾4 on the NRS scale is commonly considered to represent a
symptom with a moderate to severe intensity [23]. We have earlier found a number of patients reporting
chest pain in IPF [5]. As a subanalysis, we examined the symptom of chest pain reported in ESAS more
closely, in relation to coronary heart disease. We looked at patients treated in Helsinki University central
area, as we had access to relevant medical records. Of the 43 patients treated in Helsinki University Central
Hospital, 29 had reported chest pain in the ESAS questionnaire. We reviewed their university hospital and
the medical records for primary and secondary healthcare.
RAND-36 is a frequently used, generic HRQoL questionnaire, with 36 items across eight domains:
physical function, mental health, general health, social, mental and physical role functioning, bodily pain
and vitality [24]. It is similar to the 36-Item Short Form Survey (SF-36) [25]. The two vary only in general
health and pain scoring [24]. SF-36 is most widely used and has been previously validated and often used
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in IPF patients; however, we chose RAND-36, because it has reference values for the Finnish general
population and is intended for use as a generic measure of HRQoL. A shortened version of the SF-36,
known as SF-6D, is a single index health measure mostly utilised by health economists to calculate quality
adjusted life years (QALY) [25, 26]. In comparison to the eight dimensions of SF-36, SF-6D has no
separate general health dimension and role limitations due to emotional problems have been merged with
role limitations due to physical problems, resulting in a six-dimensional index [26, 27].
Statistical analysis
Data are presented as means with SD or as counts (n) with percentages (%).
An exploratory factor analysis with iterated principal-factor method for factoring and promax-rotated
factor loadings on correlation matrix was performed to identify related symptoms of ESAS. The strategies
used to extract the number of factors were: the Kaiser criteria, which determines that components with
eigenvalues lower than one should be excluded and the screen test of Cattell criteria. Internal consistency
was estimated by calculating Cronbach’s α internal consistency with bias corrected bootstrap 95%
confidence intervals. Adjusted correlation (partial) coefficients symptoms factors and RAND-36 domains
were calculated by the Pearson method, using Sidak adjusted probabilities. According to Cohen [28, 29],
the effect size is low if the value of r varies around 0.10, medium if r varies around 0.30, and large if r
varies more than 0.50. Stata 15.1 (StataCorp LP; College Station, Texas, USA) statistical package was used
for the analysis. In assessing relation of chest pain coronary heart disease, an independent samples t-test
was used to compare scale values and a Chi-squared test and Fisher’s Exact test were used for comparison
of categorical variables between different patient groups. A two-sided p-value <0.05 was accepted as
statistically significant.
Ethical statement
This substudy is a part of the FinnishIPF study, which has a nationwide research permit in Finland from
The National Institute for Health and Welfare (Dnro THL/1161/5.05.01/2012). In addition, approved
positive statement was received from the ethics committee of the Hospital District of Helsinki and
Uusimaa (HUS) (381/13/03/01/2014). All participants gave written informed consent.
Results
Patient characteristics are shown in table 1. Two-thirds of the patients were men and the mean time from
the diagnosis of IPF was 3.4 years (SD 2.4). Comorbidities were found in 80% of the patients, of which
cardiovascular diseases were the most common. Almost half (47%) of the patients were never-smokers.
Symptom factors
Table 2 presents three factors found in the exploratory factor analysis and the symptoms belonging to
them. The emotional factor included depression, anxiety, insomnia, nausea and loss of appetite; the pain
factor included pain at rest or in movement; and the respiratory symptoms factor included shortness of
breath, cough, tiredness and loss of wellbeing.
Cronbach’s α for the emotional factor was 0.85 (95% CI: 0.82–0.89), for the pain factor 0.78 (95% CI
0.71–0.85) and for the respiratory symptoms factor 0.78 (95% CI 0.73–0.83). There was also some
correlation between the factors: the correlation coefficient between the emotional and the pain factor was
0.57 (95% CI 0.47–0.64), the emotional and the respiratory symptoms factor 0.58 (95% CI 0.49–0.66) and
the pain and the respiratory symptoms factor 0.53 (95% CI 0.43–0.61).
Severity of the symptoms (mean NRS scores) grouped to their factors are shown in figure 1. The
respiratory symptoms factor had the highest grand mean NRS score.
Symptom factors and health-related quality of life (RAND-36)
Correlations between the symptom factors and the different domains of HRQoL measured by RAND-36
are presented in table 3. The emotional factor had the strongest correlation with mental health and vitality,
the pain factor with bodily pain and the respiratory symptoms factor with vitality, general health and
physical functioning.
Figure 2 shows the correlations of the symptom factors with SF-6D general health summary, and with the
mental and physical health summaries of the SF-6D. The emotional factor had the strongest correlation
with the mental health summary and the general SF-6D, the pain factor with physical health summary
and the respiratory symptoms factor with the physical health summary and the general SF-6D.
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Comorbidities
There was only a modest correlation between pain in movement, tiredness, shortness of breath and cough
to coronary heart disease when correlation between the different symptoms and specific comorbidities
adjusted for age and sex was analysed (supplementary table S1). No other significant correlations were
found between these groups.
In our subanalysis of patients in Helsinki University area, 29 reported chest pain in the ESAS questionnaire.
Six of them had a previous diagnosis of coronary heart disease, five received a new diagnosis and five were
TABLE 1 Patient characteristics
Age years 74 (48–92)
Men 161 (66%)








FVC# % pred 83±17
Comorbidities
Hypertension 101 (41%)







No comorbidities 48 (20%)
RAND-36 domains
Physical functioning 47±29




Social role function 73±27
Emotional role function 51±42
Mental health 72±20
Data are presented as mean (range), n (%) or mean±SD. #: FVC was recorded at the time of the diagnosis. IPF:
idiopathic pulmonary fibrosis; FVC: forced vital capacity; RAND-36: RAND 36-Item Health Survey.
TABLE 2 Exploratory factor analysis with promax-rotated factor loadings of the personal value
priorities items
Symptoms (ESAS) Emotional factor Pain factor Respiratory symptoms factor
Pain at rest 0.83






Loss of appetite 0.67
Shortness of breath 0.74
Cough 0.71
Wellbeing 0.65
Coefficients with values <0.50 not shown. The higher the coefficient, the stronger the correlation is. ESAS:
Edmonton Symptom Assessment System.
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examined for coronary heart disease but did not receive diagnosis. Thirteen patients were not examined
(supplementary table S2). Four of the patients with previous coronary heart disease required new
intervention, for two there was no obvious reason for the chest pain. For newly diagnosed coronary heart
disease, this seemed the most relevant issue behind the chest pain. No correlation between reported pain and
coronary heart disease could be found. Patients without coronary heart disease that mentioned chest pain in
medical records (n=11) had various reasons for the pain. These included degenerative findings in the
thoracic spine/ribcage (n=1), pneumonia (n=1), pericarditis (n=1) and aortic stenosis with atrial flutter
(n=1). For two patients the reason was not obvious but may have been related to gastrointestinal issues: one
had chest pain when vomiting (possible gastroenteritis) and one after use of alcohol or a large meal. For the
remaining (n=5), there seemed to be no specific reason for the pain.
Discussion
In this cross-sectional study we found three symptom factors (emotional, pain and respiratory symptoms)
in IPF patients. There was strong internal correlation and moderate correlation between the factors. The
factors correlated with different domains of HRQoL in RAND-36: the emotional factor had the strongest
correlation with mental health and vitality, the pain factor with bodily pain and the respiratory symptoms
factor with vitality, general health and physical functioning.
Shortness of breath and cough are the most common symptoms of IPF and they impair HRQoL in IPF
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FIGURE 1 Mean Numeric Rating Scale (NRS) values for each of the Edmonton Symptom Assessment System
(ESAS) symptoms, grouped according to their factors. The dashed lines indicate the grand means of
symptoms in each of the factors.
TABLE 3 Correlation between the three symptom factors and the eight domains of RAND-36,
adjusted for age and sex
RAND-36 domains Emotional factor Pain factor Respiratory symptoms factor
Physical functioning −0.39 −0.40 −0.62
General health −0.49 −0.39 −0.64
Vitality −0.63 −0.42 −0.69
Mental health −0.69 −0.36 −0.53
Physical role function −0.29 −0.31 −0.51
Emotional role function −0.39 −0.27 −0.38
Social role function −0.55 −0.36 −0.57
Bodily pain −0.48 −0.72 −0.46
All correlations are significant (Sidak adjusted probabilities p<0.001). The lower the coefficient, the
stronger the correlation is. RAND-36: RAND 36-Item Health Survey.
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four symptoms formed the respiratory symptoms factor, which showed the highest severity of symptoms.
The respiratory symptoms factor correlated with three domains of HRQoL: general health, physical
functioning and vitality (i.e. having strength and energy), showing the widespread impact of dyspnoea on
IPF patients’ wellbeing. Increasing respiratory symptoms impair physical functioning and exercise capacity,
which in turn decreases vitality and further impairs physical activity. This vicious circle of dyspnoea can
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FIGURE 2 SF-6D physical health summary, mental health summary and general SF-6D compared to the three factors (emotional factor, pain
factor and respiratory symptoms factor).
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Depression and anxiety were linked with insomnia, loss of appetite and nausea in our study. Insomnia and
loss of appetite can present as symptoms of depression [31] and nausea could be linked to both anxiety
and depression [32]. As expected, the emotional factor showed a strong correlation with mental health.
This is in line with previous studies, which show that depression and anxiety impair HRQoL in IPF
patients [33, 34]. However, the emotional factor also correlated with vitality in our study. Vitality not only
reflects physical tiredness, but also mental exhaustion, which may explain the correlation between vitality
and the emotional factor.
In contrast to the emotional and respiratory symptoms factors, pain factor had a rather specific
correlation to bodily pain in RAND-36. In our study, pain formed a factor of its own, distinct from
other symptoms. Pain, especially in movement and located on the chest, has previously been reported in
IPF patients [5]. The aetiology of pain in IPF patients remains somewhat unclear, but because pain is
not associated with the respiratory symptoms factor, it may have a mixed aetiology (e.g. musculoskeletal
pain or some other type of pain not directly associated with IPF) or associated with other comorbidities
or ageing.
Previous research on IPF symptoms is limited, and as far as we know, this is the first study to present
symptom factors in IPF. However, there are studies on clustering of symptoms in patients with other lung
diseases and in advanced cancer. HENOCH et al. [16] studied the symptoms of 400 inoperable lung cancer
patients and were able to identify three clusters of symptoms: pain (bowel problems, nausea, pain, loss of
appetite and fatigue), respiratory (coughing and dyspnoea), and mood (depression, insomnia, worry and
loss of concentration). In another study of 178 patients with advanced lung cancer and gefitinib treatment,
nausea, lack of appetite, insomnia as well as pain were in the cluster of treatment associated symptoms
instead of psychological or lung cancer symptom cluster [17]. The clustering of symptoms in the present
IPF study differed from these lung cancer studies, as in IPF patients impaired wellbeing and tiredness were
associated with respiratory symptoms, whereas nausea and loss of appetite were linked to emotional
wellbeing in IPF patients. This can be, at least partly, explained by the different symptom burden in IPF
and lung cancer. In IPF, respiratory symptoms are dominant, reflecting disease progression and impaired
overall wellbeing. In inoperable lung cancer, in addition to respiratory symptoms, pain is one of the most
significant concerns. Opioids are widely used in alleviation of cancer pain and as constipation, nausea and
drowsiness are common side effects of opioids, their association with pain is understandable.
CHEUNG et al. [11] studied 1366 patients with advanced cancer and found two clusters of symptoms: one
including fatigue, nausea, drowsiness, decreased appetite and dyspnoea and another one with depression
and anxiety. Pain had a low factor loading (<0.60) in both of the clusters, meaning it was not significantly
linked to either of them. In another study by CHEUNG et al. [12], the clustering of symptoms differed
depending on age (⩽60 and >60 years) and sex. Fatigue, drowsiness and wellbeing were not significantly
associated with either of the clusters in patients over 60 years, but in patients ⩽60 years they clustered
together with pain, depression and lack of appetite. Interestingly, fatigue, depression and anxiety changed
clusters according to sex, and in men, nausea, drowsiness and wellbeing did not belong to either of the
clusters. In our study every symptom belonged to a single factor. However, we did not look for symptom
factors according to age and sex due to the size and the age distribution of our study population.
In a relatively small study of 130 COPD patients, LIM et al. [13] found three clusters of symptoms, two of
which were in line with our factors. Their respiratory-functional cluster with dyspnoea, physical
functioning and dry mouth resembled our respiratory symptoms factor, and their mood cluster with
depression and anxiety was similar to our emotional factor. In contrast to our study, sleep problems,
which in the present study were related to the emotional factor and fatigue, which in the present study was
presented by tiredness and wellbeing of the respiratory symptoms factor, formed their own cluster.
Contrary to our study, that particular study found no separate pain cluster.
It seems, that the number and composition of symptom clusters varies between different studies, possibly
due to the heterogeneity of the study populations. Symptom factors in lung cancer, COPD and IPF were,
however, comparable to one another [13, 16, 17]. Respiratory and mental symptom factors seem to be
dominant, which is probably due to the major impact of respiratory symptoms in lung diseases and the
emotional burden of a severe life-limiting disease. However, there seems to be some variation in the
association of fatigue and insomnia depending on the study, as both can be related to emotional distress,
but also to general weakness caused by the physical symptom burden and disease progression.
The symptom factors had a significant correlation to the different domains of HRQoL in RAND-36 in our
study. Our results are in line with the findings of CHOI et al. [17], who reported that depression and lung
cancer symptoms cluster (which resembles our respiratory symptoms factor) correlate with a lower
HRQoL. LIM et al. [13] also found that in COPD patients, a higher symptom score in a symptom cluster
leads to a lower HRQoL. These two studies [13, 17], together with our study, highlight the significant
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effect that symptoms can have on HRQoL in patients with lung diseases. In the present study respiratory
and emotional symptoms had the biggest impact on HRQoL.
Study strengths and limitations
To the best of our knowledge, this is the first study to present symptom factors in IPF.
Other strengths of our study include a relatively large unselected sample of IPF patients, and symptom
evaluation in a real-life setting. However, the cross-sectional nature of our study did not allow us to study
the stability or changes of the symptom factors over time. In addition, we were not able to compare our
symptom factors to lung function tests or radiographic findings as these were not done at the same time
with the questionnaires. It was also not possible to analyse the exact data of therapy, because the
implementation of the patients’ therapy has not been monitored. For this reason, we cannot say whether the
use of oxygen and/or antifibrotic therapy could have had an impact on patients’ symptoms and wellbeing.
Conclusions
We found three symptom factors in IPF patients (respiratory symptoms, emotional and pain factor). The
respiratory symptoms factor showed the highest symptom burden and was associated with impaired overall
wellbeing. Increasing symptom burden in respiratory and emotional factors showed the strongest
association with decreasing HRQoL. In order to improve IPF patients’ general wellbeing and HRQoL,
optimal treatment of respiratory symptoms, rehabilitation and psychosocial support are vital, and routine
symptom assessment should be a part of everyday clinical practice.
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